B01AA04 - Phenprocoumon |
Propably not porphyrinogenic |
PNP |
Rationale
Phenprocoumon is metabolized by CYP 2C9, 3A4 and 2C8, but induction or inhibition of the CYP enzymes are not observed or suspected.
Chemical description
Phenprocoumon is a coumarin derivate.
Therapeutic characteristics
Phenprocoumon is a vitamin K antagonist that acts as a long acting oral anticoagulant.
It is administered orally and has a half- life of 5-9 days (Ufer 2004).
Metabolism and pharmacokinetics
In vitro, CYP2C9 and CYP3A4 is found to be the main catalyzing enzymes of the R-enantiomer of phenprocoumon hydroxylation while CYP 2C8 has part in the hydroxylation of the S-enantiomer (Ufer 2004, 2005).
No CYP relevant drug-drug interaction with phenprocoumon as a perpetrator has been reported in the literature (Drugbank, Lexi-Interact, Micromedex, SPC).
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro.
Ufer M, Svensson JO et al. Eur J Clin Pharmacol. 2004 May;60(3):173-82. |
15054565 |
| 2. | Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M. Clin Pharmacokinet. 2005;44(12):1227-46. |
16372822 |
| * | Drug reference publications | |
| 3. | DrugBank. Phenprocoumon.
|
|
| * | Drug interaction databases | |
| 4. | Lexi-Interact, via UpToDate.
|
|
| 5. | Micromedex® 2.0 (online). Drug Interactions). (24.05.2017).
|
|
Tradenames
Fenprocoumon · Marcoumar 
Marcoumar 
Marcoumar 
Marcoumar 
Marcoumar 
Marcoumar 
Liquamar · Marcoumar 
Phenprocoumone 
Fenprocumon 
Phenprocoumon